For those of you navigating stage IV breast cancer patients, you already know that approximately 70% of them have ER+, HER2- metastatic disease. Women are living far longer than ever before thanks to the evolution of CDK 4/6 inhibitors, which enable patients (especially those whose disease is limited to the bones) to have their metastatic disease treated as a chronic illness.